Faculty Summaries
Margaret von Mehren
Margaret von Mehren, MD
Professor

Publications

  • Mitchell MA, Johnson JE, Pascarelli K, Beeharry N, Chiourea M, Gagos S, Lev D, von Mehren M, Kipling D, Broccoli D. Doxorubicin Resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres. Molecular Cancer Therapeutics, 9(3):682-92. Epub Mar 2, 2010.
  • Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clinical Cancer Research 15(18):5910-6. Epub 2009 Sep 1.
  • Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of Neoadjuvant/Adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumors (GIST) – early results of RTOG 0132. Journal of Surgical Oncology, 99(1):42-7, 2009.
  • Blay J-Y, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A. Phase I Combination Study of Trabectedin and Doxorubicin in Patients With Soft Tissue Sarcoma. Clinical Cancer Research, 14:6656-6662, 2008
  • Tarn C, Rink L, Merkel E, Flieder D, Parhak H, Koumbi D, Testa J, Eisenberg B, von Mehren M, Godwin A. Insulin-like Growth Factor 1 Receptor is a Potential Therapeutic Target for Gastrointestinal Stromal Tumors. Proceedings of the National Academy of Sciences, 105(24):8387-92. Epub 2008 Jun 11, 2008.
  • von Mehren M, Schilder RJ, Cheng J, Temmer E, Cardoso T, Renshaw G, Bayever E, Zannikos P, Yuan Z, Cohen RB. A Phase I Study of the Safety and Pharmacokinetics of Trabectedin in Combination With Pegylated Liposomal Doxorubicin in Patients With Advanced Malignancies. Annals of Oncology, 19(10):1802-9, 2008.
  • Johnson J, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D. Whole-Genome Profiling in Liposarcomas Reveals Genetic Alterations Common to Specific Telomere Maintenance Mechanisms. Cancer Research, 67: 9221-9228, 2007.
  • Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK. Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms. Cancer Research, 66(10):5477-86, 2006.
  • Johnson JE, Varkonyi RJ, Schwalm J, Cragle R, Klein-Szanto A, Patchefsky A, Cukierman E, von Mehren M, Broccoli D. Multiple Mechanisms of Telomere Maintenance exist in Liposarcomas. Clinical Cancer Research, 11(15):5347-55, 2005.
  • Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogayko YV, Heslin M, Eisenberg B, Birbe R, Patchefsky A, Dunbrack R, Arnoletti JB, von Mehren M, Godwin AK. Analysis of Kit mutations in Sporadic and Familial GIST: Therapeutic Implications using Protein Modeling. Clinical Cancer Research, 11(10):3668-77, 2005.
  • von Mehren M, Balcerzak SI, Kraft AS, Edmonson EK, Okuno SH, Davey M, McLaughlin S, Beard MT, and Rogatko A. Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma, 8(4):107-112, 2004.
  • Frolov A, Chahwan S, Ochs M, Arnoletti, JP, Pan Z-Z, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors (GISTs). Molecular Cancer Therapeutics 2(8):699-709, 2003.
  • Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 347(7):472-480, 2002.
Top